Center for Targeted Therapeutics and Translational Nanomedicine (CT³N)

CT3N News Archive

  • Penn Medicines Garret FitzGerald MD FRS Elected to the German National Academy of Sciences

    Thursday, June 7, 2018

    Garret FitzGerald, MD, FRS, a professor of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine at the University of Pennsylvania, and an international leader in cardiovascular disease research, has been elected to the Leopoldina, the German National Academy of Sciences, the oldest continuously existing academy of medicine and the natural sciences in the world. The award recognizes FitzGerald’s “scientific achievements and … personal standing.” He has been selected for membership in the Academy’s section on physiology and pharmacology/toxicology.

  • Penn-led Trial Shows AZEDRA Can Be Effective, Safe for Treatment of Rare Neuroendocrine Tumors [PI: Daniel A. Pryma]

    Tuesday, May 29, 2018

    A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania. The study showed AZEDRA led to a significant reduction in the cardiovascular side effects that are associated with these cancers while also stopping tumor growth. The study’s principal investigator Daniel A. Pryma, MD, Chief of Nuclear Medicine and Clinical Molecular Imaging at Penn’s Perelman School of Medicine, will present the results at the ASCO 2018 Annual Meeting in Chicago.

  • Penn Medicine Researcher, James Eberwine, Joins International Collaboration to Better Understand How Cells Regulate Energy Production

    Friday, May 4, 2018

    James Eberwine, PhD, the Elmer Holmes Bobst Professor of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine at the University of Pennsylvania, is part of an international team of researchers, who will receive $1.25M over the next three years to better understand oxidative phosphorylation (OxPhos), a biological system that plays a key role in the production of energy, generation of free radicals, and cell death.

  • Calculus III for cells [Kathleen Stebe quoted]

    Monday, April 23, 2018

    Last year, researchers from the University of Pennsylvania revealed surprising insights into how cells respond to surface curvature. "We think of it as the cells doing calculus; the cells sense and respond to the underlying curvature,” says Kathleen Stebe of Penn’s School of Engineering and Applied Science. Now, the researchers, led by Stebe and recent engineering graduate Nathan Bade in collaboration with Randall Kamien of the School of Arts and Sciences and Richard Assoian of the Perelman School of Medicine, have published a follow up study that Stebe likens to “calc III” for cells, investigating how cells respond to more complex geometries. The research, which could enable new tools in biology and affect how physicians treat things like vascular disease, has been published in the Biophysical Journal.

  • Penn Cancer Researchers Receive $2.7 Million from V Foundation to Better Understand PARP Inhibitors and Treat BRCA Cancers [Roger A. Greenberg]

    Thursday, March 29, 2018

    Cancer researchers from the Perelman School of Medicine at the University of Pennsylvania and the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania, have received two major grants from the V Foundation for Cancer Research. Funded projects will work to better understand and treat cancers in patients with inherited mutations of the BRCA1 and BRCA2 genes, which produce tumor-suppressor proteins. These mutations significantly increase the risk for breast and ovarian cancer as well as other types of cancer in women and men. The first grant, a three-year, $2.1 M Team Science Convergence Award, will be led by Roger A. Greenberg, MD, PHD, a professor of Cancer Biology, and Katherine L. Nathanson, MD, a professor of Medicine and Genetics.

  • A fake organ mimics what happens in the blink of an eye [Dan Huh]

    Tuesday, February 20, 2018

    For the first time, researchers used human cells to build a model of the surface of the eye that’s equipped with a fake eyelid that mimics blinking. This synthetic eye could be used to study and test treatments for eye diseases, researchers reported February 16 in a news conference at the annual meeting of the American Association for the Advancement of Science. This artificial eye is made of corneal cells (dark blue) surrounded by a ring of conjunctival cells (white), grown on a contact lens‒like surface. The device “blinks” when a hydrogel film slides over a channel containing artificial tears (black) and spreads the liquid over the cells. Dan Huh, a bioengineer at the University of Pennsylvania, and colleagues grew a ring of conjunctival cells — tissue that covers the white part of the eye — around a circle of corneal cells on a contact lens‒shaped platform. A faux eyelid made of a thin hydrogel film covers and uncovers the eye to spread tear fluid over the cells.

  • Jason Burdick Receives Heilmeier Research Award

    Jason Burdick, Professor in Bioengineering, has been named the recipient of the 2017-18 George H. Heilmeier Faculty Award for Excellence in Research for "pioneering contributions to designing and developing polymers for applications in stem cell biology and regenerative medicine." The Heilmeier Award honors a Penn Engineering faculty member whose work is scientifically meritorious and has high technological impact and visibility. It is named for George H. Heilmeier, a Penn Engineering alumnus and overseer whose technological contributions include the development of liquid crystal displays and whose honors include the National Medal of Science and Kyoto Prize. Burdick's research interests include developing degradable polymeric biomaterials that can be used for tissue engineering, drug delivery, and fundamental polymer studies.

  • Penn Researchers Develop an Injectable Gel that Helps Heart Muscle Regenerate after a Heart Attack [Jason Burdick]

    Wednesday, November 29, 2017

    In mammals, including humans, the cells that contract the heart muscle and enable it to beat do not regenerate after injury. After a heart attack, there is a dramatic loss of these heart muscle cells and those that survive cannot effectively replicate. With fewer of these contractile cells, known as cardiomyocytes, the heart pumps less blood with each beat, leading to the increased mortality associated with heart disease. Now, researchers at the University of Pennsylvania’s School of Engineering and Applied Science and Perelman School of Medicine have used mouse models to demonstrate a new approach to restart replication in existing cardiomyocytes: an injectable gel that slowly releases short gene sequences known as microRNAs into the heart muscle. The study was led by Edward Morrisey, Professor in Medicine, member of the Cell and Molecular Biology graduate group and Scientific Director of the Penn Institute for Regenerative Medicine in Penn Medicine; Jason Burdick, Professor in Bioengineering in Penn Engineering; Leo Wang, a graduate student in Burdick’s lab; and Ying Liu, a postdoctoral researcher in Morrisey’s lab. It was published in the journal Nature Biomedical Engineering.

  • First Microscopic Video of Blood Clot Contraction Reveals How Platelets Naturally Form Unobtrusive Clots [Team led by John W. Weisel]

    Wednesday, November 8, 2017

    The first view of the physical mechanism of how a blood clot contracts at the level of individual platelets is giving researchers from the Perelman School of Medicine at the University of Pennsylvania a new look at a natural process that is part of blood clotting. A team led by John W. Weisel, PhD, a professor of Cell and Developmental Biology, describes in Nature Communications how specialized proteins in platelets cause clots to shrink in size. To learn how a clot contracts, the Penn team imaged clots (networks of fibrin fibers and blood platelets) using an imaging technique called confocal light microscopy. The natural process of clot contraction is necessary for the body to effectively stem bleeding, reduce the size of otherwise obstructive clots, and promote wound healing. The physical mechanism of platelet-driven clot contraction they observed is already informing new ways to think about diagnosing and treating conditions such as ischemic stroke, deep vein thrombosis, and heart attacks. In all of these conditions, clots are located where they should not be and block blood flow to critical parts of the body. Evidence from a study published earlier this year from the Weisel lab suggests that platelets in people with these diseases are less effective at clot contraction, thereby contributing to clots being more obstructive. “Under normal circumstances, blood clot contraction plays an important role in preventing bleeding by making a better seal, since the cells become tightly packed as the spaces between them are eliminated,” Weisel said. “In this study, we unwrapped and quantified clot contraction in single platelets.” The team quantified the structural details of how contracting platelets cause clots to shrink, accompanied by dramatic structural alterations of the platelet-fibrin meshwork.

  • Penn Researchers Working to Mimic Giant Clams to Enhance the Production of Biofuel [Shu Yang]

    Thursday, November 2, 2017

    Alison Sweeney of the University of Pennsylvania has been studying giant clams since she was a postdoctoral fellow at the University of California, Santa Barbara. These large mollusks, which anchor themselves to coral reefs in the tropical waters of the Indian and Pacific oceans, can grow to up to three-feet long and weigh hundreds of pounds. But their size isn’t the only thing that makes them unique. Anyone who has ever gone snorkeling in Australia or the western tropical Pacific Ocean, Sweeney says, may have noticed that the surfaces of giant clams are iridescent, appearing to sparkle before the naked eye. The lustrous cells on the surface of the clam scatter bright sunlight, which typically runs the risk of causing fatal damage to the cell, but the clams efficiently convert the sunlight into fuel. Using what they learn from these giant clams, the researchers hope to improve the process of producing biofuel. Sweeney, an assistant professor of physics in the Penn School of Arts and Sciences, and her collaborator Shu Yang, a professor of materials science and engineering in the School of Engineering and Applied Science, refer to the clams as “solar transformers” because they are capable of absorbing bright sunlight at a very high rate and scattering it over a large surface area. When the light is distributed evenly among the thick layer of algae living inside the clam, the algae quickly converts the light into energy. After coming across Sweeney’s work, Yang struck up a collaboration to see if they could mimic the system by abstracting the principles of the clam’s process to create a material that works similarly. She and Ph.D. student Hye-Na Kim devised a method of synthesizing nanoparticles and adding them to an emulsion — a mixture of water, oil, and soapy molecules called surfactants — to form microbeads mimicking the iridocytes, the cells in giant clams responsible for solar transforming. Their paper has been published in Advanced Materials.

  • Penn Engineers Develop Filters That Use Nanoparticles to Prevent Slime Build-up [Study was led by Daeyeon Lee]

    Wednesday, November 1, 2017

    Filtration membranes are, at their core, sponge-like materials that have micro- or nanoscopically small pores. Unwanted chemicals, bacteria and even viruses are physically blocked by the maze of mesh, but liquids like water can make it through. The current standard for making these filters is relatively straightforward, but doesn’t allow for much in the way of giving them additional functionality. This is a particular need when it comes to “biofouling.” The biological material they are supposed to filter out — including bacteria and viruses— gets stuck on the surface of the mesh, blocking the pores with a slimy residue. Beyond reducing the flow, such biofilms can potentially contaminate whatever liquid makes it through to the other side of the filter. Researchers at the University of Pennsylvania’s School of Engineering and Applied Science have a new way of making membranes that could address this problem. Their method allows them to add in a host of new abilities via functional nanoparticles that adhere to the surface of the mesh. They have demonstrated this new process with membranes that block bacteria- and virus-sized contaminants without letting them stick, a property that would vastly increase the efficiency and lifespan of the filter. The “antifouling” membranes they have tested would be immediately useful in relatively simple applications, like filtering drinking water, and could eventually be used on the oily compounds found in fracking wastewater and other heavy-duty pollutants. The researchers’ method, described in a paper recently published in the journal Nature Communications, allows for membranes made from a wide range of polymers and nanoparticles. Beyond antifouling abilities, future nanoparticles could catalyze reactions with the contaminants, destroying them or even converting them into something useful. The study was led by Daeyeon Lee, a professor in Penn Engineering’s Department of Chemical and Biomolecular Engineering, and Kathleen Stebe, Penn Engineering’s Deputy Dean for Research and Richer & Elizabeth Goodwin Professor of Chemical and Biomolecular Engineering, along with Martin F. Haase, an assistant professor at Rowan University who developed the technology as a postdoctoral researcher in the labs of Stebe and Lee. Harim Jeon, Noah Hough, and Jong Hak Kim also contributed to the study.

  • Robert Carpick Named 2017 MRS Fellow

    Wednesday, September 20, 2017

    Robert Carpick, John Henry Towne Professor and Chair in the Department of Mechanical Engineering and Applied Mechanics, has been named a Fellow of the Materials Research Society (MRS) Fellow. The fellowship honors those MRS members who are notable for their distinguished research accomplishments and their outstanding contributions to the advancement of materials research, worldwide. Dr. Carpick was recognized by the MRS "for fundamental insights into the nanometer scale mechanics of materials and atomic scale origins of friction, lubrication, and wear." The distinction is highly selective with the maximum number of new Fellow appointments each year being limited to 0.2% of the current MRS regular membership.

  • Organs on Chips [Dan Huh]

    Monday, August 28, 2017

    Scientists hope that these devices will one day replace animal models of disease and help advance personalized medicine. Dan Huh, a bioengineering professor at the University of Pennsylvania who was a postdoc in Ingber’s lab, and colleagues have created an eye-on-a-chip—with an eyelid that blinks. This chip, which is roughly the size and shape of a contact lens, approximates the ocular surface of the eye. It contains human cells from the cornea and conjunctiva (the mucosal layer that covers the eye). The team also engineered an eyelid, which attaches to the surface and allows the eye to blink, keeping the surface of the chip lubricated.

  • How DNA Damage Turns Immune Cells Against Cancer [Roger Greenberg]

    Monday, July 31, 2017

    Findings Suggest Modifying the Cell Replication Cycle Could Make Combo Therapies More Successful

  • Cancer survivor becomes a cancer fighter at a Philly start-up [Andrew Tsourkas and David Cormode]

    Friday, July 28, 2017

    What Debra Travers really wanted to be was a marine biologist, until “I found out Jacques Cousteau wasn’t hiring.” How she wound up as chief executive of PolyAurum LLC, a Philadelphia start-up developing biodegradable gold nanoparticles for treating cancerous tumors, involved a professional journey of more than 30 years in pharmaceutical and diagnostics industries, and a personal battle with the disease she’s now in business to defeat.Penn’s David Cormode, a professor of radiology, and Andrew Tsourkas, a professor of bioengineering, have worked to make gold more biocompatible, resulting in PolyAurum’s current technology, Dorsey said. The gold nanocrystals are contained in a biodegradable polymer that allows enough metal to collect in a tumor. The polymer then breaks down, releasing the gold for excretion from the body so that it does not build up in key organs.

  • Penn Researchers Engineer Macrophages to Engulf Cancer Cells in Solid Tumors [Led by Dennis Discher]

    Thursday, July 6, 2017

    The research was led by Dennis E. Discher, the Robert D. Bent Professor in Penn Engineering’s Department of Chemical and Bimolecular Engineering, and Cory Alvey, a graduate student in his lab from the Department of Pharmacology in Penn Medicine.

  • Penn Engineers Show Key Feature for Modeling How Cells Spread in Fibrous Environments

    Friday, May 26, 2017

    The study, published in the Proceedings of the National Academy of Sciences, was led by Vivek Shenoy, professor in the Department of Materials Science and Engineering and co-director of Penn’s Center for Engineering Mechanobiology, along with Xuan Cao and Ehsan Ban, members of his lab. They collaborated with Jason Burdick, professor in the Department of Bioengineering

  • Garret FitzGerald Receives American Heart Association Merit Award to Enhance Blood Pressure Control

    Wednesday, May 24, 2017

    Merit Awards Support “Visionary Leaders”

  • Penn Neuroscientist Receives Scientific Innovations Award from the Brain Research Foundation

    Tuesday, March 21, 2017

    PHILADELPHIA— James Eberwine, PhD, the Elmer Holmes Bobst Professor of Systems Pharmacology and Translational Therapeutics at the Perelman School of Medicine at the University of Pennsylvania, has received the 2017 Scientific Innovations Award from the Chicago-based Brain Research Foundation, which supports research for preventing and treating neurological diseases.

  • Turning Patients' Cells into Therapeutic Antibody Factories - Podcast

    Thursday, March 2, 2017

    Turning Patients' Cells into Therapeutic Antibody Factories - Sounds of Science Podcast

  • Powerful RNA-based Technology Could Help Shape the Future of Therapeutic Antibodies

    Thursday, March 2, 2017

    PHILADELPHIA—Using antibodies to treat disease has been one of the great success stories of early 21st-century medicine. Already five of the ten top-selling pharmaceuticals in the United States are antibody products. But antibodies are large, complex proteins that can be expensive to manufacture. Now, a team led by scientists from the Perelman School of Medicine at the University of Pennsylvania demonstrates in an animal model a new way to deliver safer and more cost-effective therapeutic antibodies. “We showed that you can give 1/40th the dose of mRNA compared to the antibody protein itself, and completely protect mice from HIV infection when they are exposed to the virus,” said senior author Drew Weissman, MD, PhD, a professor of Infectious Diseases. “Clinical trials of this anti-HIV antibody are already underway, but we think our mRNA approach could in principle be a very effective alternative to this and other antibody therapies.”

  • Penn Medicine: New Zika Vaccine Candidate Protects Mice and Monkeys with a Single Dose

    Thursday, February 2, 2017

    A new Zika vaccine candidate has the potential to protect against the virus with a single dose, according to a research team led by scientists from the Perelman School of Medicine at the University of Pennsylvania. As reported in Nature this week, preclinical tests showed promising immune responses in both mice and monkeys.“We observed rapid and durable protective immunity without adverse events, and so we think this candidate vaccine represents a promising strategy for the global fight against Zika virus,” said senior author Drew Weissman, MD, PhD, a professor of Infectious Disease at Penn. “We hope to start clinical trials in 12 to 18 months.”

  • Penn Engineering and Medicine come together to lead the Center for Targeted Therapeutics and Translational Nanomedicine

    Friday, November 4, 2016

    Penn Engineering and Medicine come together to lead the Center for Targeted Therapeutics and Translational Nanomedicine

  • Penn Engineering Launches Collaboration with the Center for Targeted Therapeutics and Translational Nanomedicine (CT3N)

    Tuesday, October 18, 2016

    Penn Engineering Launches Collaboration with the Center for Targeted Therapeutics and Translational Nanomedicine (CT3N)

  • Penn Medicine Professor Receives Distinguished Service Award for the Irish Abroad

    Thursday, September 22, 2016

    Garret A. FitzGerald, MD, FRS, Chair of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine at the University of Pennsylvania, has received a 2016 Presidential Distinguished Service Award for the Irish Abroad.

  • Penn Researchers Improve Computer Modeling for Designing Drug-delivery Nanocarriers

    Tuesday, August 2, 2016

    Penn Researchers Improve Computer Modeling for Designing Drug-delivery Nanocarriers

  • Penn Team Uses Nanoparticles to Break Up Plaque and Prevent Cavities

    Monday, July 25, 2016

    Penn Team Uses Nanoparticles to Break Up Plaque and Prevent Cavities

  • Penn Prof. Theresa Busch and Genisphere collaborate on targeted nanotherapeutics for photodynamic therapy

    Tuesday, March 22, 2016

    Penn Professor Theresa Busch and Genisphere collaborate on targeted nanotherapeutics for photodynamic therapy

  • Penn Pioneer in Translational Medicine Remarks on New National Academy of Sciences Report on Precision Medicine

    Friday, March 4, 2016

    Comprehensive strategies to ensure that patients have access to effective biomarker tests and treatments will be essential to access the potential of precision medicine, according to a new report entitled Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine released today by the National Academies of Sciences, Engineering, and Medicine (NAS).

  • Penn-Engineered Neural Networks Show Hope for Axonal Repair in the Brain, with Minimal Disruption to Brain Tissue

    Tuesday, January 19, 2016

    Lab-grown neural networks have the ability to replace lost axonal tracks in the brains of patients with severe head injuries, strokes or neurodegenerative diseases and can be safely delivered with minimal disruption to brain tissue, according to new research from Penn Medicine's department of Neurosurgical Research.

  • T Cells That Recognize HER2 Receptor May Be Key to Preventing HER2+ Breast Cancer Recurrence, Penn Study Finds

    Wednesday, December 30, 2015

    Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient's immune system – a weakness that in principle could be corrected with a HER2-targeted vaccine – according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

  • High Response Rates, Long-Term Remissions Seen In Penn Trials of Personalized Cellular Therapy CTL019 for Pediatric and Adult Blood Cancers

    Monday, December 7, 2015

    Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over one year in 18 patients and over two years in nine patients.

  • New Approach to Treating Heparin-induced Blood Disorder Revealed in Structure of Protein-Antibody Complex, Penn Study Finds

    Tuesday, October 6, 2015

    A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root, according to new research from the Perelman School of Medicine at the University of Pennsylvania. 

  • Penn-developed, DNA-based Vaccine Clears Nearly Half of Precancerous Cervical Lesions in Clinical Trial

    Wednesday, September 30, 2015

    Using a novel synthetic platform for creating vaccines originally developed in the laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine from the Perelman School of Medicine at the University of Pennsylvania, a team led by his colleagues at the Johns Hopkins University School of Medicine, has successfully eradicated precancerous cervical lesions in nearly half of the women who received the investigational vaccine in a clinical trial.

  • Penn Team Pinpoints Immune Changes in Blood of Melanoma Patients on PD-1 Drugs That Put Potential Biomarker within Reach

    Wednesday, September 16, 2015

    A simple blood test can detect early markers of "reinvigorated" T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab, researchers from the Abramson Cancer Center of the University of Pennsylvania report in new research being presented at the inaugural CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.

  • Abramson Cancer Center Researchers Report Long-Term Remissions in First Group of Patients to Receive Personalized Cellular Therapy for Chronic Lymphocytic Leukemia

    Wednesday, September 2, 2015

    Eight of 14 patients in the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing past four and a half years.

  • Investigational T-cell Receptor Therapy Achieves Encouraging Clinical Responses in Multiple Myeloma Patients, Penn-led Study Finds

    Monday, July 20, 2015

    Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

  • Penn Researchers' New Tracking Method Yields Insights into Mitochondrial Dynamics

    Wednesday, July 1, 2015

    Mitochondria, the tiny oxygen reactors that power our cells, can be the keys to health or disease. But while the recognition of their importance has soared in recent years, methods for studying them haven't always kept pace. Now, scientists from the Perelman School of Medicine at the University of Pennsylvania have devised a powerful new technique that enables the tracking of every mitochondrion as it moves within a cell.

  • Penn Study Indicates that Gene Therapy Efficacy for LCA is Dynamic: Improvement is Followed by Decline in Vision

    Monday, May 4, 2015

    Gene therapy for Leber congenital amaurosis (LCA), an inherited disorder that causes loss of night- and day-vision starting in childhood, improved patients' eyesight within weeks of treatment in a clinical trial of 15 children and adults at the Scheie Eye Institute at the Perelman School of Medicine at the University of Pennsylvania.

  • New Combination of Immunotherapy Drugs is Safe, Shrinks Tumors in Metastatic Melanoma Patients, Penn Study Finds

    Sunday, April 19, 2015

    Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

  • Investigational Personalized Cellular Therapy Tolerated Well by Patients with Advanced Mesothelioma, Ovarian and Pancreatic Cancers

    Sunday, April 19, 2015

    Genetically modified versions of patients' own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of Pennsylvania.

  • Immunotherapy Drug Pembrolizumab Shows Early Promise for Mesothelioma Patients, Penn Medicine Researchers Find

    Sunday, April 19, 2015

    The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

  • Penn Study Describes First Steps in Basic Biological Process that Could be Harnessed to Make Therapeutic Cells

    Thursday, April 16, 2015

    Understanding the molecular signals that guide early cells in the embryo to develop into different types of organs provides insight into how tissues regenerate and repair themselves. By knowing the principles that underlie the intricate steps in this transformation, researchers will be able to make new cells at will for transplantation and tissue repair in such situations as liver or heart disease.

  • Blinking Cells: Penn Neuroscientist-Led Team is Finalist in NIH "Follow that Cell" Challenge to Fund Single Cell Biology

    Wednesday, April 1, 2015

    James Eberwine, PhD, the Elmer Holmes Bobst Professor of Systems Pharmacology and Experimental Therapeutics, at the Perelman School of Medicine at the University of Pennsylvania, was named one of 16 finalists in the first phase of the Follow that Cell Challenge funded by the National Institutes of Health (NIH).

  • Two Penn Medicine Gene Therapy Researchers Receive Pennsylvania Bio Awards

    Wednesday, March 11, 2015

    Two researchers from the Perelman School of Medicine at the University of Pennsylvania will be honored for their contributions for the burgeoning field of gene therapy by Pennsylvania Bio at their annual dinner this week.

  • Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

    Wednesday, March 11, 2015

    University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy.

  • Radiation Plus Immunotherapy Combo Revs up Immune System to Better Attack Metastatic Melanoma, Penn Study Suggests

    Monday, March 9, 2015

    Treating metastatic melanoma with a triple threat—including radiation therapy and two immunotherapies that target the CTLA4 and PD-1 pathways—could elicit an optimal response in more patients, one that will boost the immune system's attack on the disease, suggests a new study from a multidisciplinary team of researchers from Penn's Abramson Cancer Center published today in Nature.

  • Penn Medicine Study Describes Development of Personalized Cellular Therapy for Brain Cancer

    Wednesday, February 18, 2015

    Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. The results paved the way for a newly opened clinical trial for glioblastoma patients at Penn.

  • Penn Medicine's New Immunotherapy Study Will Pit PD-1 Inhibitor Against Advanced Lung Cancer

    Tuesday, February 3, 2015

    Penn Medicine researchers have begun a new immunotherapy trial with the "checkpoint inhibitor" known as pembrolizumab in patients with oligometastatic lung cancer—a state characterized by a few metastases in a confined area—who have completed conventional treatments and are considered free of active disease but remain at a high risk for recurrence. 

  • Penn Researchers Show Value of Tissue-Engineering to Repair Major Peripheral Nerve Injuries

    Friday, January 30, 2015

    Peripheral nerve injury (PNI) is a common consequence of traumatic injuries, wounds caused by an external force or an act of violence, such as a car accident, gun shot or even surgery. In those injuries that require surgical reconstruction, outcomes can result in partial or complete loss of nerve function and a reduced quality of life. But, researchers at Penn Medicine have demonstrated a novel way to regenerate long-distance nerve connections in animal models using tissue-engineered nerve grafts (TENGs).

Center for Targeted Therapeutics and Translational Nanomedicine

Institute for Translational Medicine and Therapeutics (ITMAT)
10-125 Smilow Center for Translational Research
3400 Civic Center Blvd.
Philadelphia, PA 19104-5158